EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome

X Charlene Liao iD, Tao Huang iD, David S Hong iD, Liqun Luo iD

JCEM Case Reports · 20.05.2026 · 4 (7)

DOI: 10.1210/jcemcr/luag152 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 03.06.2026. Verfasst von X Charlene Liao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Independent Scholar, Palo Alto, CA 94303, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Smith–Magenis syndrome (SMS) is a rare neurodevelopmental disorder characterized by intellectual disability, behavioral dysregulation, and hyperphagia-driven obesity. While dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated efficacy in the general population, their use in patients with SMS has not been described. We report the case of a 31-year-old woman with SMS (17p11.2 deletion) treated with tirzepatide, a dual GIP/GLP-1 receptor agonist. The patient presented with lifelong obesity (body mass index [BMI] 32.0-32.9 kg/m2 in adulthood) and aggressive behaviors refractory to standard management. Following initiation of tirzepatide, titrated to 5 mg weekly, she achieved 9.4% weight loss (7.3 kg) over 10 months, along with improvement in fasting glucose levels. Concurrently, caregivers reported notable behavioral improvements, including reduced food-seeking behavior and impulsivity. Quantitative analysis demonstrated a significant reduction in aggression. The treatment was well tolerated. This case suggests that tirzepatide may represent a promising therapeutic option for SMS, targeting both metabolic and central nervous system pathways involved in its phenotype.

Schlagwörter

Stichwörter der Autor:innen

Smith-Magenis syndromebehavior managementsyndromic obesitytherapeutic strategytirzepatide

Autor:innen und Institutionen

  • Independent Scholar, Palo Alto, CA 94303, USA.
  • Independent Scholar, Mountain View, CA 94041, USA.
  • Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.
  • Howard Hughes Medical Institute, Department of Biology, Stanford University, Stanford, CA 94305, USA.

ORCID-Profile: X Charlene Liao, Tao Huang, David S Hong, Liqun Luo

Zitieren

APA

Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026). Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome. JCEM Case Reports, 4(7). https://doi.org/10.1210/jcemcr/luag152

Vancouver

Liao XC, Huang T, Hong DS, Luo L. Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome. JCEM Case Reports. 2026;4(7). doi:10.1210/jcemcr/luag152

BibTeX
@article{Liao2026,
  author = {Liao, X Charlene and Huang, Tao and Hong, David S and Luo, Liqun},
  title = {Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {7},
  doi = {10.1210/jcemcr/luag152}
}
Kostenlos starten →